What CyGenica does
Founded in 2017, CyGenica operates in Health Tech offering non-viral, non-toxic delivery solutions for drugs, gene editing components, and antibiotics. The company focuses on overcoming the cellular membrane barrier that limits the effective delivery of large therapeutic molecules, particularly in gene therapy. By enhancing the delivery of therapeutics into target cells, CyGenica aims to reduce unwanted side effects and lower dosage requirements. The founder's personal experience with her father's cancer treatment drives the team to improve the safety and effectiveness of cancer drugs, striving to make a positive impact on patient outcomes globally.
Who runs it
Funding and finances
Why this matters to you: funding stage is a rough proxy for how long the runway is and how much structure to expect. It is not a promise, and a profitable bootstrapped company can be the safer bet.
Check the company’s own careers page — linked at the top — before a job board. A role appears there first, sometimes weeks before it is syndicated anywhere else.
Questions and experiences
Nobody has asked anything about CyGenica yet. If you have interviewed here, what you know is worth more to the next person than anything on the rest of this page.
Company facts compiled from public sources and last refreshed 9 September 2026. Details change; treat the company’s own site as the authority.